Galapagos | Booth A19

50th Annual Meeting of the EBMT​

We are united around our mission to redefine the future of cancer treatment. Our goal is to help people facing cancer live longer, better lives. Our hope is fueled by the dream of a future free from cancer.

About Galapagos
Our focus in Oncology
CAR T at Point of Care
Oral presentation
Scientific presence
Clinical trials

Pioneering for patients

Who we are

Galapagos is a fully integrated biotechnology company united around a single purpose: to transform patient outcomes through life-changing science and innovation for more years of life and quality of life. We focus on the key therapeutic areas of immunology and oncology, where we have developed deep scientific expertise in multiple drug modalities, including small molecules and cell therapies.

Galapagos factsheetAbout us

Redefining the Future of Cancer Treatment

Cancer is a complex disease with no one-size-fits-all solution. At Galapagos, our dedication lies in taking a holistic approach to tackle cancer. We’re at the forefront of developing innovative tactics that target cancer from multiple angles.

Our approach involves a diverse set of tools and strategies, including small molecules, antibody-based biological therapies, novel chimeric antigen receptor (CAR) T-cell therapies, ingenious manufacturing technologies, and various other pioneering approaches to address the complexity of cancer.

Our Innovation Areas

Our focus in oncology

Delivering more years of life and improving the quality of life

Non-Hodgkin’s lymphoma (NHL)

Read more

Chronic lymphocytic leukemia (CLL), including Richter transformation (RT)

Read more

Multiple myeloma (MM)

Read more

Our innovative approach to CAR T manufacturing at the Point of Care

Galapagos’ decentralized, innovative Point-of-Care CAR T manufacturing platform consists of:

  • a proprietary end-to-end xCellit® workflow management and monitoring software system,
  • a decentralized, functionally closed, automated manufacturing platform for cell therapies (using Lonza’s Cocoon®) and
  • a proprietary quality control (QC) testing and release strategy.

The combination of these three core components offers the potential for the administration of a fresh product with a vein-to-vein time of 7 days (i.e. the time between T-cell collection and CAR T infusion), and greater physicians’ oversight throughout the process.

The Cocoon® Platform is a registered trademark of Lonza Group AG

Novel manufacturing technology

We are committed to manufacture personalized cell therapies at the Point of Care,
right where patients are

Novel Point-of-Care
supply model

Galapagos’ decentralized Point-of-Care
CAR T manufacturing model, consists of a proprietary xCellit® workflow management and monitoring software, a manufacturing platform for cell therapies (using Lonza’s Cocoon®) and a proprietary quality control (QC) testing and release strategy

Greater physicians’
oversight

Enables clinicians to administer fresh CAR T cells without complex logistics or cryopreservation and provides greater oversight for physicians during the process

Faster solutions
for patients

Ability to reduce the average vein-to-vein time (i.e. time between T-cell collection and CAR T infusion) from months to days

Our scientific presence at the 50th Annual Meeting of the EBMT​

RESULTS FROM THE PHASE 1
ATALANTA-1 TRIAL​​

SEVEN-DAY VEIN-TO-VEIN POINT-OF-CARE–MANUFACTURED CD19 CAR T-CELL THERAPY (GLPG5101) IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL)

Oral Presentation
Wednesday, 17 April, 12:57 – 13:06​​
Hall 2

Marie José Kersten1, Kirsten Saevels2, Sophie Servais3, Yves Beguin3, Joost S. P. Vermaat4, Eva Santermans5, Stavros Milatos6, Maike Spoon7, Marte C. Liefaard7, Claire Vennin7, Margot J. Pont7, Anna D.D. van Muyden7, Maria T. Kuipers1, Sébastien Anguille2

1University of Amsterdam, Amsterdam, Netherlands, 2Antwerp University Hospital, Antwerp, Belgium, 3Centre Hospitalier Universitaire de Liège, Liège, Belgium, 4Leiden University Medical Center, Leiden, Netherlands, 5Galapagos NV, Mechelen, Belgium, 6Galapagos GmbH, Basel, Switzerland, 7Galapagos BV, Oegstgeest, Netherlands

RESULTS FROM THE PHASE 1
EUPLAGIA-1 STUDY​​

SEVEN-DAY VEIN-TO-VEIN POINT-OF-CARE–MANUFACTURED CD19 CAR T-CELL THERAPY (GLPG5201) IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA INCLUDING RICHTER TRANSFORMATION

Oral Presentation
Wednesday, 17 April, 13:06 – 13:15​​
Hall 2

Valentín Ortiz-Maldonado1, Nuria Martinez-Cibrian1, Julio Delgado1, Sergi Betriu1, Leticia Alserawan1, Ana Triguero1, Nadia Verbruggen2, Maike Spoon3, Marte C. Liefaard3, Anna D.D. van Muyden3, Natalia Tovar1

1Hospital Clínic de Barcelona, Barcelona, Spain, 2Galapagos NV, Mechelen, Belgium, 3Galapagos BV, Oegstgeest, Netherlands

All Galapagos abstracts

Oral presentation number: OS16-04

  • Date: 17 April, 12:57–13:06 (session runs from 12:30–13:45)
  • Session: Oral Session 16: CAR-T outcomes in ALL
  • Presenter: Yves Beguin

Authors: Marie José Kersten, Kirsten Saevels, Sophie Servais, Yves Beguin, Joost S.P. Vermaat, Eva Santermans, Stavros Milatos, Maike Spoon, Marte C. Liefaard, Claire Vennin, Margot J. Pont, Anna D.D. van Muyden, Maria T. Kuipers, Sébastien Anguille

Oral presentation number: OS16-05

  • Date: 17 April, 13:06-13:15 (session runs 12:30-13:45)
  • Session: Oral Session 16: CAR-T outcomes in ALL
  • Presenter: Valentin Ortiz-Maldonado

Authors: Valentin Ortiz-Maldonado, Nuria Martinez-Cibrian, Julio Delgado, Sergi Betriu, Leticia Alserawan, Ana Triguero, Nadia Verbruggen, Maike Spoon, Marte C. Liefaard, Anna D.D. van Muyden, Natalia Tova

Poster number: A073

  • Date: 15 April, 18:00-19:00
  • Session: Printed poster: CAR-based Cellular Therapy – Clinical
  • Presenter: Esmée P. Hoefsmit

Authors: Esmée P. Hoefsmit, Sandra Blum, Claire Vennin, Kirsten Van Hoorde, Sergi Betriu,
Leticia Alserawan, Julio Delgado, Nadia Verbruggen, Anna D.D. van Muyden, Henriëtte Rozema, Ruiz Astigarraga, Margot J. Pont

Poster number: P049

  • Date: 14 April, 08:30-18:00
  • Session: ePoster: CAR-based Cellular Therapy – Clinical
  • Presenter: Anna D.D. van Muyden

Authors: Niels W.C.J. van de Donk, Sébastien Anguille, Jo Caers, Marte C. Liefaard, Christian Jacques, Anna D.D. van Muyden

Our clinical trials in Oncology

The ATALANTA-1 study is a phase 1/2 multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured GLPG5101 in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma (rrNHL).
EudraCT 2021-003272-13

Key eligibility criteria

  • rrNHL: DLBCL, MCL, FL, MZL, HR DLBCL, BL and PCNSL
  • DLBCL, HR DLBCL, BL and PCNSL are allowed if primary refractory or relapse after 1 line of treatment
  • FL, MZL and MCL are allowed after ≥ 2 lines of treatment

More information

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5101) in Relapsed/Refractory NHL: Results from the Phase 1 Atalanta-1 Trial

The EUPLAGIA-1 study is a phase 1/2 study to evaluate the feasibility, safety, and efficacy of point-of-care manufactured GLPG5201 in subjects with relapsed/refractory chronic lymphocytic leukemia (rrCLL) or small lymphocytic lymphoma (rrSLL), including Richter’s transformation
EudraCT 2021-003815-25

Key eligibility criteria

  • CD19+ rrCLL or rrSLL, Richter transformation included:
    • CLL patients must have been exposed to at least 2 prior lines, including BTK inhibitors, BCL2 inhibitors, and/or PI3K inhibitors
    • Richter patients who failed a BTK inhibitor are eligible regardless of number of prior therapy lines received
  • No prior CD19-targeted therapies

More information

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL Including Richter’s Transformation: Results from the Phase 1 Euplagia-1 Trial

The PAPILIO-1 study is a phase 1/2 open-label, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured GLPG5301 in subjects with relapsed/refractory multiple myeloma (rrMM)
EudraCT 2022-500782-27-00

Key eligibility criteria

  • rrMM, plasma cell leukemia included, after at least 2 prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and anti-CD38 antibody treatment
  • No prior BCMA-targeted therapies

More information

Rationale for and Design of Papilio-1: A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Feasibility, Safety, and Efficacy of Point-of-Care–Manufactured Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells (GLPG5301) in Relapsed/Refractory Multiple Myeloma

Our clinical pipeline in oncology

In our quest to advance cancer care, we focus on addressing the unique needs of patients with hematological malignancies.

Discover our pipeline in Oncology and Immunology

Let’s connect!

Visit the Galapagos booth A19

Join our expanding
Point-of-Care network!

Given the initial results of our ongoing clinical trials, we are currently expanding the Point-of-Care network across the US and Europe.

Contact us for more information about the opportunities to join our ongoing and planned clinical studies.

GL-ONCO (CT)–202404-00002

Factsheet

Our commitment in oncology

Do you need everything in one place about our efforts in redefining the future of cancer treatments?

Our Oncology Factsheet